To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

This study has been completed.
Information provided by:
Sandoz Identifier:
First received: June 2, 2009
Last updated: June 3, 2009
Last verified: June 2009

To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.

Condition Intervention Phase
Drug: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Drug: Alprazolam Tablets, 1 mg (The Upjohn Company)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bioavailability of Alprazolam Tablets

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 13 days ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: November 1991
Study Completion Date: November 1991
Primary Completion Date: November 1991 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Drug: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Active Comparator: 2
Alprazolam Tablets, 1 mg (The Upjohn Company)
Drug: Alprazolam Tablets, 1 mg (The Upjohn Company)


Ages Eligible for Study:   19 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Please refer to this study by its identifier: NCT00913341

Sponsors and Collaborators
Sandoz Inc.
Principal Investigator: Niloufar Guiv, M.D. PharmaKinetics Laboratories, Inc.
  More Information

No publications provided

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc. Identifier: NCT00913341     History of Changes
Other Study ID Numbers: 9153A
Study First Received: June 2, 2009
Last Updated: June 3, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 23, 2014